Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

被引:35
|
作者
Brims, Fraser [1 ,2 ,3 ]
机构
[1] Curtin Univ, Curtin Med Sch, Perth, WA 6845, Australia
[2] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6009, Australia
[3] Inst Resp Hlth, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia
关键词
mesothelioma; asbestos; epidemiology; pleural disease; TO-LYMPHOCYTE RATIO; PROGNOSTIC-FACTORS; OPEN-LABEL; TALC PLEURODESIS; LUNG-CANCER; SOLUBLE MESOTHELIN; SERUM MESOTHELIN; PHASE-III; DIAGNOSIS; ASBESTOS;
D O I
10.3390/cancers13164194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known safe level of asbestos exposure. Symptoms of mesothelioma can include worsening breathlessness, chest pain and loss of weight. There is no cure, and the treatment of mesothelioma is limited, although there have been some recent improvements in therapy. Survival is very variable although most people live for around one year after diagnosis. Efforts to improve and maintain the quality of life for patients with mesothelioma remain a priority. Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9-12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] STUDY OF SOME FACTORS RELATED TO EPIDEMIOLOGY IN MALIGNANT PLEURAL MESOTHELIOMA
    Lam, Nguyen S.
    Thanh, Tran D.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S990 - S990
  • [32] Malignant mesothelioma
    Rudd, R. M.
    BRITISH MEDICAL BULLETIN, 2010, 93 (01) : 105 - 123
  • [33] Malignant Pleural Mesothelioma: Factors Influencing the Prognosis
    Mineo, Tommaso Claudio
    Ambrogi, Vincenzo
    ONCOLOGY-NEW YORK, 2012, 26 (12): : 1164 - 1175
  • [34] Pleural mesothelioma in Poland: Spatial analysis of malignant mesothelioma prevalence in the period 1999-2013
    Krowczynska, Malgorzata
    Wilk, Ewa
    Pabjanek, Piotr
    Oledzka, Gabriela
    GEOSPATIAL HEALTH, 2018, 13 (02) : 314 - 321
  • [35] Comprehensive clinical overview of malignant pleural mesothelioma
    Khan, Agha Muhammad Hammad
    Anwer, Shaikh Hasan
    Sayed, Samad
    Mansha, Muhammad Atif
    Bin Kamran, Yazdan
    Khursheed, Afrah
    Haroon, Fahd
    Soomro, Niaz Hussain
    Idrees, Romana
    Abbasi, Ahmed Nadeem
    RESPIRATORY MEDICINE, 2024, 222
  • [36] Turkish Clinical Guideline for Malignant Pleural Mesothelioma
    Metintas, Muzaffer
    EURASIAN JOURNAL OF PULMONOLOGY, 2015, 17 : 1 - 21
  • [37] Clinical practice guidelines for malignant pleural mesothelioma
    van Zandwijk, Nico
    JOURNAL OF THORACIC DISEASE, 2013, 5 (06) : 724 - 725
  • [38] Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma
    Creaney, Jenette
    Dick, Ian M.
    Segal, Amanda
    Musk, Arthur W.
    Robinson, Bruce W. S.
    LUNG CANCER, 2013, 82 (03) : 491 - 498
  • [39] CLINICAL ASPECTS OF MALIGNANT MESOTHELIOMA IN AUSTRALIA
    DRISCOLL, TR
    BAKER, GJ
    DANIELS, S
    LEE, J
    THOMPSON, R
    FERGUSON, DA
    LEIGH, J
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1993, 23 (01): : 19 - 25
  • [40] Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
    Cristaudo, Alfonso
    Bonotti, Alessandra
    Simonini, Silvia
    Vivaldi, Agnese
    Guglielmi, Giovanni
    Ambrosino, Nicolino
    Chella, Antonio
    Lucchi, Marco
    Mussi, Alfredo
    Foddis, Rudy
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1587 - 1593